An interventional study of Increase in the PEEP followed by decrease in the PEEP and Decrease in the PEEP followed by increase in the PEEP in Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia and Extreme Prematurity, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 7 Days to 30 Days. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies in Bronchopulmonary Dysplasia with a site in United States — 29 open to participants now, 36 under way, 1 of them phase 3. Bronchopulmonary Dysplasia · United States.
Among the 147 studies in Bronchopulmonary Dysplasia with a site in United States, this one is the 86th largest by planned enrollment of the 117 interventional ones that give a count, is one of 12 that started in 2026, is one of 46 with no phase, reaches primary completion later than 15 of the 35 other live ones, and was the 132nd registered.
363 studies on the registry are indexed under Bronchopulmonary Dysplasia; 85 are open to participants now.
Browse Bronchopulmonary Dysplasia studies →29 of the 147 studies in Bronchopulmonary Dysplasia with a site in United States are open now. Recruiting first, the newest first:
NICHD Neonatal Research Network · Sites in United States
Ages up to 31 wk
University of Alabama at Birmingham · Sites in United States
Ages 1 mo–5 mo · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 1 days–3 days
Augusta University · Sites in United States
Ages 25 wk–34 wk
Indiana University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 57 Bronchopulmonary Dysplasia studies recruiting now, 6 (11%) set no upper age limit and 50 (88%) stop at 75 or younger; 55 take children under 18; 11 take healthy volunteers.
This study: 7 Days to 30 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 36 · Phase 3 20 · Phase 4 7
First in 1991; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 66 across 244 interventional studies indexed under Bronchopulmonary Dysplasia.
Median enrollment 50 across the 117 interventional studies, 155 across the 30 observational. Of the 100 that completed or were terminated, 42 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 147 have an industry lead sponsor. The 10 most frequent:
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
University of Alabama at Birmingham has 9 studies filed under Bronchopulmonary Dysplasia — fewer than ten, so there is no comparison to draw.
19 of the studies in Bronchopulmonary Dysplasia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT03797183University of Colorado, DenverGenesis Electrical Impedance Tomography (EIT): A Preliminary Study | 2026-11 |
| NCT04372953Murdoch Childrens Research InstitutePositive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial). | 2026-11-30 |
| NCT05568264Shirley Ryan AbilityLabEffects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit | 2026-12-31 |
| NCT07447739Khang NguyenCan Betamethasone Given After Birth Help Extremely Premature Babies Come Off Breathing Support Safely and Effectively? | 2027-03 |
Add all 19 to your calendar (.ics) → With an account.
Among the 147 studies in Bronchopulmonary Dysplasia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In preterm infants \< 34 weeks' gestation at birth receiving respiratory support with invasive positive pressure ventilation, the positive end-expiratory pressure (PEEP) of best compliance will increase the cardiac output and improve oxygenation. This study may emphasize using point-of-care echocardiography along with electrical impedance tomography (EIT) to optimize ventilator settings in preterm infants.
Infants will be randomized to a 4-hour crossover period of increasing and decreasing PEEP in random order from baseline to determine compliance, oxygenation, and cardiac hemodynamics at each step using echocardiography (ECHO) and EIT measurements. There will be a 15-minute washout period after changes prior to data collection.
In preterm infants \< 34 weeks' gestation at birth receiving respiratory support with invasive positive pressure ventilation, the positive end-expiratory pressure (PEEP) of best compliance will increase the cardiac output and improve oxygenation. This study may emphasize using point-of-care echocardiography along with EIT to optimize ventilator settings in preterm infants.
Neonatal ventilation is a critical intervention to support breathing for newborns with respiratory distress syndrome (RDS), underdeveloped lungs, and evolving bronchopulmonary dysplasia (BPD). Positive airway pressure helps maintain patency of the airways and improves ventilation and oxygenation by maintaining the functional residual capacity (FRC) and keeping the alveoli patent. Peak inspiratory pressure (PIP) and positive end-expiratory pressure (PEEP) are terms commonly used in mechanical ventilation to describe the pressures applied to the respiratory system during the different phases of the breathing cycle. These parameters are essential in managing and optimizing ventilation for infants with respiratory failure.
This study will include preterm infants with recovering RDS born at age \< 34 weeks of gestational age on respiratory support via conventional mechanical ventilation or on high-frequency jet ventilation (HFJV). Infants will be randomized to the order of testing, increasing the PEEP (+1 cmH2O and +2 cmH2O) or decreasing the PEEP (+1 cmH2O and +2 cmH2O) with baseline measurements and Echo done at original PEEP and each subsequent PEEP.
Following informed consent, randomization will be performed using sequentially numbered sealed opaque envelopes. The randomization envelope will be signed before it is opened just before starting the study on each infant to indicate the first intervention for the infant.
This will be a single-center, randomized crossover study. The randomization envelope will be signed before it is opened just before starting the study on each infant to indicate the first intervention for the infant.
Randomization will occur after a baseline assessment of cardiac hemodynamics and respiratory status at the current set PEEP level. Infants will be randomized to the order of changes in PEEP levels during mechanical ventilation - increase followed by decrease versus decrease followed by increase. Randomization will use opaque sealed envelopes of varying block sizes from 2-4 with a 1:1:1:1 allocation ratio.
Infants will be randomized to a 4-hour crossover period of increasing and decreasing PEEP in random order from baseline and there will be a 15-minute washout period after changes before data collection.
All infants enrolled in the study will have routine monitoring, uniform target saturation ranges of 91-95% with alarm limits set at 88-95%, and standard care for the duration of the study. Pulse oximetry recordings will be downloaded using ixTrend (iexcellence, Wildau, Germany) software to a secure computer system for later data analysis.
Infants will continue standard treatment as recommended by the treating physician and will act as their own controls.
Primary secondary outcomes are described below. Electrical impedance tomography data will be collected in the Syntec machine and safely secured in the university computer system. Pulse oximetry recordings will be downloaded using ixTrend software to a secure computer system for later data analysis.
ECHO results will be stored in the unit ECHO machine and results will be reported by certified cardiologists blinded to the data collected to improve the study design's internal and external validity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Preterm infants with recovering respiratory distress syndrome (RDS) who were born at a gestational age \< 34 weeks and are receiving respiratory support via conventional mechanical ventilation or on HFJV.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infants will be randomized to the order of changes in PEEP levels during mechanical ventilation - increase followed by decrease in PEEP. Baseline parameters looking into cardiac hemodynamics as well as compliance and respiratory mechanics will be assessed using EIT
Other: Increase in the PEEP followed by decrease in the PEEP
Infants will be randomized to the order of changes in PEEP levels during mechanical ventilation - decrease followed by increase in PEEP. Baseline parameters looking into cardiac hemodynamics as well as compliance and respiratory mechanics will be assessed using EIT
Other: Decrease in the PEEP followed by increase in the PEEP
Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics
Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics
Change in cardiac index with increase/decrease in PEEP as measured by ECHO and EIT
Time frame: During a 4 hour cross-over period on either intervention
PEEP of best compliance and best oxygenation as per EIT measurements
Time frame: During a 4 hour cross-over period on either intervention
Tidal volume variation
Time frame: During a 4 hour cross-over period on either intervention
Oxygen saturation index
Time frame: During a 4 hour cross-over period on either intervention
End-expiratory lung impedance (EELI), End-inspiratory lung impedance (EILI)
Time frame: During a 4 hour cross-over period on either intervention
Transcutaneous carbon dioxide (TcCO2) values in response to varying PEEP levels
Time frame: During a 4 hour cross-over period on either intervention
Respiratory Severity Score (RSS)
RSS: mean airway pressure (MAP) x fraction of inspired oxygen (FiO2)
Time frame: During a 4 hour cross-over period on either intervention
oxygen saturation (SpO2) values
Time frame: During a 4 hour cross-over period on either intervention
% tidal distribution
Time frame: During a 4 hour cross-over period on either intervention
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for May 2027, 7 months after the start.
Of 71 non-industry interventional studies with no phase under Bronchopulmonary Dysplasia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 7 months is below that.
Counting every sponsor, half of 73 studies reached it within 37 months; a quarter within 19 and three quarters within 63.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 26, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →